Kewaunee Scientific posts presentation for 2026 annual shareholder meeting
KEQU•Strategy and governance points
The deck outlined no proposals for shareholder votes. Strategy emphasized international expansion, a new Spain entity, systems, and SOX 404(b) readiness.
Segment revenue and backlog details
- Lab Products Group segment revenue rose to $214.9 million from $179.4 million.
- International revenue was $67.1 million from $61.1 million.
- Backlog ended at $165.9 million, up from $214.6 million.
- Lab Products Group backlog was $118.8 million.
- International backlog was $47.1 million.
Shareholder meeting deck highlights FY2026 results
Kewaunee Scientific shareholder meeting deck highlighted FY2026 revenue of $282 million, EBITDA of $22.4 million, and pre-tax earnings of $13.7 million.
- Net earnings were .
